Oncology drug discovery and development company, ADC Therapeutics, has closed its Series E financing expansion, in which it raised $103 million.
Oncology drug discovery and development company, ADC Therapeutics, has closed its Series E financing expansion, in which it raised $103 million, it was announced in a July 9, 2019 press statement.
The total funds raised in the Series E financing round, after the closure of the expansion, stands at $303 million, which includes a $25 million investment from a new institutional investor based in the United States. Other investment has been raised from existing investors.
With the raised funds, the company plans to complete enrolment in its Phase II trial of ADCT-402, which is being assessed in patients with refractorydiffuse large B-cell lymphoma (DLBCL). Additionally, the company plans to use the funds to start a Phase II trial of ADCT-301 in patients with relapsed or refractory Hodgkin’s lymphoma.
Chris Martin, chief executive officer of ADC Therapeutics, said, “We are delighted to welcome a new blue-chip institutional investor to our shareholder base. This financing provides us with a strong balance sheet to fund preparations for a potential biologics license application (BLA) for ADCT-402 (loncastuximab tesirine) in relapsed or refractory DLBCL in the second half of 2020, as well as for initiating in the coming months a pivotal Phase II trial of ADCT-301 (camidanlumab tesirine) in Hodgkin’s lymphoma based on our recent end of Phase I meeting with the US Food and Drug Administration.”
Source: ADC Therapeutics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.